Concert Pharmaceuticals Inc(NASDAQ:CNCE) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Aug 9, 2016. Company reported revenue of $71.00K. Analysts estimated a revenue of $30.00K. Earnings per share were $-0.60. Analysts had estimated an EPS of $-0.63.
Concert Pharmaceuticals Inc (CNCE) shares turned negative on Wednesdays trading session with the shares closing down -0.02 points or -0.18% at a volume of 72,197. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $11.01. The peak price level was also seen at $11.01 while the days lowest was $10.6701. Finally the shares closed at $10.99. The 52-week high of the shares is $25.04 while the 52-week low is $9.8. According to the latest information available, the market cap of the company is $244 M.
Several Insider Transactions has been reported to the SEC. On May 16, 2016, Thomas G Auchincloss (director) purchased 2,000 shares at $10.11 per share price.Also, On May 12, 2016, Roger D Tung (CEO) purchased 19,610 shares at $10.55 per share price.On Dec 17, 2015, Richard Aldrich (director) sold 20,000 shares at $19.76 per share price, according to the Form-4 filing with the securities and exchange commission.
Concert Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company applying its DCE Platform to create novel small molecule drugs. The Company’s approach starts with approved drugs advanced clinical candidates or previously studied compounds that have the potential to be improved with deuterium substitution to enhance clinical safety tolerability and efficacy. It has a pipeline of wholly owned and collaboration programs. The Company has a number of clinical candidates under development such as CTP-656 which is a product candidate for the treatment of cystic fibrosis; AVP-786 which is being investigated for treatment of neurologic and psychiatric disorders including Alzheimers agitation; CTP-730 which is a product candidate for the treatment of inflammatory diseases and JZP-386 which is a product candidate for the treatment of narcolepsy.